GlassScriptPhysician profile
Brandon L Houk
NPI 1518143577
$1,228.82
in general payments reported to CMS, 2019-2025
21 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $149 · 2021: $230 · 2022: $27.77 · 2023: $87.07 · 2024: $29.89 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $267.82 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $141.23 | 2019-2024 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $104.57 | 2019 | |
| Amgen INC. | $43.69 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $42.91 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.60 | 2019-2023 | Trintellix |
| Allergan, INC. | $31.70 | 2019-2020 | |
| Indivior INC. | $29.29 | 2019-2024 | Sublocade |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $21.61 | 2019 | |
| Braeburn INC. | $21.50 | 2025 | Brixadi |
| Antares Pharma, INC. | $19.33 | 2020 | |
| Abbott Laboratories | $18.44 | 2019 | |
| Cipher Pharmaceuticals US LLC | $17.03 | 2025 | Spinosad, Natroba |
| Halozyme INC | $15.33 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $14.91 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.76 | 2022 | |
| Corcept Therapeutics | $14.16 | 2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.86 | 2019 | |
| Merck Sharp & Dohme LLC | $11.62 | 2019 | |
| Supernus Pharmaceuticals, INC. | $10.96 | 2019 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Houk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.